Phase 2 Heart Disease Trial, Recruiting (NCT07397351)

Phase 2 Heart Disease Trial, Recruiting NCT07397351 Sponsor: Research Institute of Geroprotective Technologies Condition: Heart Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07397351 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Heart Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have coronary artery disease where one or more heart arteries are significantly narrowed, and who have been recommended for a planned (non-emergency) procedure to open the artery and place a stent — this includes people with stable chest pain or heart disease caused by a previous heart attack or artery hardening.
People whose heart artery narrowing has been confirmed by an imaging test called a coronary angiogram, showing that a stent procedure is needed.
People aged between 50 and 80 years old at the time of signing the consent form.
People whose blood test result for a heart-related protein called high-sensitivity troponin I is within the normal range, ruling out a recent or ongoing heart attack.
People who have been fully informed about the study and have signed a written consent form agreeing to take part voluntarily.
People who are willing and able to attend all required study visits and follow all study procedures as outlined in the plan.

Who may not be able to join:

No specific exclusion criteria were listed in the source document. (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 7 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07397351

Sponsor: Research Institute of Geroprotective Technologies

Phase: Phase 2

Status: Recruiting

Condition: Heart Disease

More information: https://clinicaltrials.gov/study/NCT07397351

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have coronary artery disease where one or more heart arteries are significantly narrowed, and who have been recommended for a planned (non-emergency) procedure to open the artery and place a stent — this includes people with stable chest pain or heart disease caused by a previous heart attack or artery hardening.
People whose heart artery narrowing has been confirmed by an imaging test called a coronary angiogram, showing that a stent procedure is needed.
People aged between 50 and 80 years old at the time of signing the consent form.
People whose blood test result for a heart-related protein called high-sensitivity troponin I is within the normal range, ruling out a recent or ongoing heart attack.
People who have been fully informed about the study and have signed a written consent form agreeing to take part voluntarily.
People who are willing and able to attend all required study visits and follow all study procedures as outlined in the plan.

Who may not be able to join:

No specific exclusion criteria were listed in the source document. (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 7 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Research Institute of Geroprotective Technologies

Registry

ClinicalTrials.gov

Start date

5 March 2026

Est. completion

1 October 2026

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

Incremental area under the concentration-time curve (iAUC) of high-sensitivity troponin I (hs-cTnI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov